A Phase 2, Rapid Response, Open-Label Study to Assess Safety and Immunogenicity of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Adults in an Outbreak Setting
Latest Information Update: 22 Apr 2025
At a glance
- Drugs VRC MARADC087 00 VP (Primary)
- Indications Marburg virus disease
- Focus Adverse reactions
Most Recent Events
- 22 Apr 2025 New trial record
- 16 Apr 2025 According to Sabin Vaccine Institute media release, Data from the this trial will be shared with Sabin to support the vaccine licensure.